QIAGEN

QIAGEN

QIAGEN was founded in 1984 by a team of researchers from the University of Düsseldorf who commercialized a new method for purifying nucleic acids. The company listed on the Nasdaq in 1996 and moved its legal seat to the Netherlands in 2013 while retaining its German operational headquarters in Hilden. CEO Thierry Bernard, who joined in 2015 and assumed the top role in 2020, previously ran QIAGEN's molecular diagnostics business, the segment that now generates roughly half of company revenue. QIAGEN's assets span sample preparation, assay technologies, bioinformatics, and automation systems across molecular diagnostics and life-science research. The portfolio covers infectious disease testing, cancer companion diagnostics, forensic DNA analysis, and veterinary screening. In November 2023, QIAGEN acquired Verogen, the forensic genomics company built on Illumina's next-generation sequencing technology (per the firm, November 2023). The company operates a direct co-investment model through its QIAGEN Digital Insights unit, which licenses curated biomedical databases and clinical-decision support tools to pharmaceutical firms including AstraZeneca and Pfizer. Geographic revenue is split across the Americas, EMEA, and Asia-Pacific. QIAGEN employs roughly 6,000 people with major facilities in Germantown, Maryland, Hilden, Germany, and Manchester, UK. The firm's installed base of automated sample-preparation instruments — the QIAsymphony and EZ1 lines — creates recurring consumable revenue that Philanthropic structures are absent from the firm's public disclosures, though the QIAGEN Foundation partners with disease-specific nonprofits in tuberculosis and leprosy screening. In November 2023, QIAGEN acquired Verogen to add forensic genetic genealogy to its criminal-justice portfolio (per the firm, November 2023). QIAGEN's structural moat lies in regulatory inertia — sample-preparation protocols validated on its chemistry are not easily swapped out of FDA-cleared or laboratory-developed tests. That consumable lock-in turns each instrument placement into an annuity stream that competitors cannot replicate without triggering a laboratory revalidation process. The firm's hybrid identity as both a diagnostics manufacturer and a bioinformatics software provider places it at the intersection of wet-lab chemistry and AI-driven genomic interpretation.